Key result
IABP successfully treats sunitinib-related cardiogenic shock, improving LVEF to 48%.
Why the study?
Unanticipated cardiotoxicity related to tyrosine kinase inhibitors including sunitinib malate has been reported, but treatment and prognosis of sunitinib-related cardiogenic shock are less well described.
Comparison
Intra-aortic balloon counterpulsation treatment
Design
Case report
Authors
Loading...
Hypothesis-generating for IABP in sunitinib-induced cardiogenic shock; prospective studies needed before adoption.
Case Report (n=1)
Intra-aortic balloon counterpulsation can successfully support patients with sunitinib-induced cardiogenic shock who cannot tolerate standard heart failure medical therapy.
Wu et al. (2009) conducted a case report in Sunitinib malate-related cardiomyopathy and cardiogenic shock (n=1). Intra-aortic balloon counterpulsation was evaluated on Survival and left ventricular ejection fraction improvement. Intra-aortic balloon counterpulsation successfully treated sunitinib-related cardiogenic shock, with left ventricular ejection fraction improving from 20% to 48% at 24 days and no late gadolinium enhancement on cardiac MRI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: